ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Sold by Chase Investment Counsel Corp

Chase Investment Counsel Corp decreased its holdings in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) by 14.8% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 8,980 shares of the exchange traded fund’s stock after selling 1,555 shares during the period. Chase Investment Counsel Corp owned approximately 0.65% of ProShares Ultra Nasdaq Biotechnology worth $572,000 at the end of the most recent quarter.

Separately, Texas Capital Bank Wealth Management Services Inc purchased a new stake in ProShares Ultra Nasdaq Biotechnology during the 1st quarter worth approximately $288,000.

ProShares Ultra Nasdaq Biotechnology Stock Down 5.4 %

NASDAQ BIB opened at $62.76 on Wednesday. ProShares Ultra Nasdaq Biotechnology has a 12-month low of $40.70 and a 12-month high of $69.56. The company has a fifty day simple moving average of $63.82 and a two-hundred day simple moving average of $61.84.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The company also recently declared a dividend, which was paid on Wednesday, October 2nd. Shareholders of record on Wednesday, September 25th were given a dividend of $0.1528 per share. The ex-dividend date was Wednesday, September 25th. This is a boost from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.04.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.